Transcriptional and Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Genini, Davide ^a   Garcia Escudero, Ramon ^b   Carbone, Giuseppina M ^a   Catapano, Carlo V ^a  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b CIEMAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P85ALPHA; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR INTERACTION; POSITIVE FEEDBACK; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; RECEPTOR BINDING; TRANSCRIPTION REGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; INFLAMMATION; LUNG NEOPLASMS; PHOSPHORYLATION; PPAR DELTA; PPAR-BETA; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 84866641956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046009     Document Type: Article

References (42)

1. Michalik L, Desvergne B, Wahli W, (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70.
2. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, et al. (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 97: 13275-13280.
3. He TC, Chan TA, Vogelstein B, Kinzler KW, (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
4. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, et al. (2004) Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64: 3162-3170.
5. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, et al. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247.
6. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295.
7. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, et al. (2005) Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950-3957.
8. Park BH, Vogelstein B, Kinzler KW, (2001) Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 98: 2598-2603.
9. Peters JM, Shah YM, Gonzalez FJ, (2012) The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12: 181-195.
10. Barak Y, Liao D, He W, Ong ES, Nelson MC, et al. (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99: 303-308.
11. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, et al. (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10: 481-483.
12. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, et al. (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23: 8992-8996.
13. Genini D, Catapano CV, (2007) Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity. J Biol Chem 282: 11776-11785.
14. Genini D, Carbone GM, Catapano CV, (2008) Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res 2008: 195065.
15. Gupta RA, Dubois RN, (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
16. Ermert L, Dierkes C, Ermert M, (2003) Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 9: 1604-1610.
17. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, et al. (2002) Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 277: 23534-23543.
18. Wang D, Wang H, Guo Y, Ning W, Katkuri S, et al. (2006) Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 103: 19069-19074.
19. Sun S, Schiller JH, Spinola M, Minna JD, (2007) New molecularly targeted therapies for lung cancer. J Clin Invest 117: 2740-2750.
20. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, et al. (2006) Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861.
21. Napoli S, Pastori C, Magistri M, Carbone GM, Catapano CV, (2009) Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J 28: 1708-1719.
22. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP, (2008) Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 39: 689-696.
23. Peters JM, Foreman JE, Gonzalez FJ, (2011) Dissecting the role of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in colon, breast, and lung carcinogenesis. Cancer Metastasis Rev 30: 619-640.
24. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B, (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10: 721-733.
25. Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, et al. (2007) Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 104: 12890-12895.
26. Glass CK, Ogawa S, (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6: 44-55.
27. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, et al. (2008) Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor {beta}/{delta} (NR1C2) Antagonist. Mol Endocrinol 22: 523-529.
28. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, et al. (2005) PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 8: 373-379.
29. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
30. Han JK, Lee HS, Yang HM, Hur J, Jun SI, et al. (2008) Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 118: 1021-1033.
31. Han S, Ritzenthaler JD, Zheng Y, Roman J, (2008) PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol 294: L1238-1249.
32. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, et al. (2008) Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73: 709-717.
33. Han S, Ritzenthaler JD, Sun X, Zheng Y, Roman J, (2009) Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. Am J Respir Cell Mol Biol 40: 325-331.
34. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N, (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129: 723-733.
35. Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E, (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308: 361-368.
36. Yoshinaga M, Taki K, Somada S, Sakiyama Y, Kubo N, et al. (2011) The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci 56: 1194-1200.
37. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, et al. (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541.
38. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, et al. (2003) Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 278: 42992-43000.
39. Zhou H, Liu W, Su Y, Wei Z, Liu J, et al. (2010) NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 17: 560-573.
40. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
41. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, et al. (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64: 5897-5904.
42. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, et al. (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila) 1: 349-356.